MedTrace Logo

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

NCT00909766 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2015-11-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and effect on body weight and other obesity-related factors of different doses of BMS-830216, compared to placebo. The study will also determine the amount of BMS-830216 in the blood.

Conditions

Interventions

DRUG

BMS-830216

Capsules, Oral, 30 mg, once daily, 28 days

DRUG

BMS-830216

Capsules, Oral, 100 mg, once daily, 28 days

DRUG

BMS-830216

Capsules, oral, 300 mg, once daily, 28 days

DRUG

BMS-830216

Capsules, oral, 600 mg, once daily 28 days

DRUG

BMS-830216

Capsules, oral, 1200 mg, once daily, 28 days

DRUG

BMS-830216

Capsules, Oral, to be determined, once daily, 28 days

DRUG

Placebo

Capsules, Oral, 0 mg, once daily, 28 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00909766 on ClinicalTrials.gov